Global Adult Vaccines Market Outlook, 2029

The adult vaccines market has seen significant evolution over the years, reflecting broader trends in public health and medical advancements. Historically, vaccines were primarily associated with childhood immunization, targeting diseases like measles and polio. However, the concept of adult vaccination began to gain traction in the late 20th century as the understanding of infectious diseases broadened. Key milestones include the development of vaccines for influenza, pneumococcus, and shingles, which address health concerns prevalent in older adults and those with specific health conditions. This market encompasses vaccines for a range of conditions, including influenza, hepatitis, human papillomavirus (HPV), and newer innovations targeting emerging threats. Economic factors, aging populations, and rising healthcare costs have also contributed to the market's growth, as preventive measures are often seen as cost-effective compared to treating diseases after they occur. Global health policies have increasingly emphasized the importance of vaccination as a cornerstone of public health. The introduction of universal immunization programs and vaccination schedules for adults, coupled with global initiatives like the Global Vaccine Summit, reflects a broader recognition of the need for adult immunization. Regulation and policy play crucial roles in shaping the adult vaccines market. In the United States, the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) are primary regulatory bodies overseeing vaccine safety, efficacy, and distribution. The Advisory Committee on Immunization Practices (ACIP) provides recommendations for vaccine use, which influence public health policies and insurance coverage. Similarly, in Europe, the European Medicines Agency (EMA) oversees vaccine regulation, while the World Health Organization (WHO) provides global guidance and support.

According to the research report "Global Adult Vaccines Market Overview, 2029," published by Bonafide Research, the Global Adult Vaccines market was valued at more than USD 18 Billion in 2023. The adult vaccines market has experienced robust growth and transformation, driven by advancements in medical technology, increasing awareness of preventive healthcare, and the rising burden of infectious diseases. Key players in this market include major pharmaceutical companies such as Pfizer, GlaxoSmithKline (GSK), Merck & Co., and Sanofi. These companies are leading the development and distribution of vaccines across various segments, including influenza, pneumococcal diseases, and shingles, as well as emerging areas such as vaccines for respiratory syncytial virus (RSV) and cancer. Pfizer and Merck & Co., for instance, are prominent in the production of vaccines like Prevnar 13, a multivalent conjugate vaccine targeting multiple strains of pneumococcus, and Gardasil, an HPV vaccine. GSK is known for its FluLaval and Shingrix vaccines, addressing influenza and shingles, respectively. Sanofi’s contributions include vaccines for flu and meningococcal disease, demonstrating its extensive role in the adult vaccine market. The market’s growth trajectory is underpinned by several factors. The aging global population, coupled with increased healthcare awareness, has driven demand for vaccines that prevent age-related diseases and reduce healthcare costs. Additionally, the COVID-19 pandemic highlighted the importance of vaccines in controlling infectious diseases, accelerating research and investment in vaccine development.

Market Drivers
Increasing Disease Burden: The incidence of vaccine-preventable diseases among adults, such as influenza, pneumococcal disease, and shingles, is a major driver for the adult vaccines market. Chronic conditions like chronic obstructive pulmonary disease (COPD) and diabetes can also increase susceptibility to infections, making vaccination more important.
Health Recommendations and Guidelines: Increasing awareness among healthcare providers and patients about the importance of adult vaccination is driving market growth. Guidelines and recommendations from health organizations, such as the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO), emphasize the need for vaccines like influenza, hepatitis, and shingles for adults.

Market Challenges
Misinformation and Skepticism: Vaccine hesitancy remains a significant challenge, influenced by misinformation, skepticism about vaccine safety, and general distrust in the healthcare system. Overcoming these barriers requires targeted communication strategies and educational efforts to build trust and emphasize the benefits of vaccination.
High Cost and Accessibility Issues: The cost of adult vaccines can be high, particularly for those not covered by insurance or public health programs. Economic barriers can limit access to vaccines and affect vaccination rates, particularly in low-income populations. Integrating adult vaccines into existing healthcare systems and ensuring that vaccines are easily accessible to all adults can be challenging. This includes addressing logistical issues related to vaccine distribution, storage, and administration.

Market Trends
Innovation in Vaccine Technology: Advances in vaccine technology are leading to the development of new and improved vaccines for adults. This includes vaccines with enhanced efficacy, fewer side effects, and better safety profiles. For example, newer influenza vaccines offer broader protection against multiple strains.
Preventive Health Measures: There is an increasing emphasis on preventive health measures, including vaccination, to improve overall health outcomes and reduce healthcare costs. Preventive measures are becoming a key component of adult healthcare, with a focus on preventing diseases before they occur.




based on the report, the types are segmented into Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccines.
These vaccines reflect a nuanced approach to disease prevention, catering to varying needs and health conditions in adult populations. Monovalent Conjugate Vaccines are formulated to target a single pathogen or strain. These vaccines combine a polysaccharide from the pathogen with a protein carrier to enhance the immune response. Despite their focus on a single antigen, monovalent conjugate vaccines play a crucial role in protecting against specific diseases. For adults, these vaccines are often utilized for diseases where targeted protection is necessary, such as the Haemophilus influenzae type b (Hib) vaccine. Historically, Hib vaccines were primarily used in children, but emerging evidence supports their use in certain adult populations, particularly those with specific health conditions or in outbreak situations. Multivalent Conjugate Vaccines, in contrast, offer broader protection by including antigens from multiple strains or serotypes of a pathogen within a single vaccine. This approach is advantageous in addressing a wider range of disease-causing organisms. For example, the pneumococcal conjugate vaccines (PCV) protect against multiple serotypes of Streptococcus pneumoniae, which can cause severe infections such as pneumonia and meningitis. The ability of multivalent vaccines to provide comprehensive protection with a single dose makes them particularly valuable in adult immunization programs. They are effective in preventing diseases that pose significant risks to older adults and those with weakened immune systems.

based on the report, the Disease type is segmented into Varicella, Human Papilloma Virus, Measles, Mumps and Rubella, Pneumococcal Disease and others.
Historically, varicella vaccination has been focused on children, but increasing evidence supports its use in adults, especially those who are unvaccinated or at higher risk due to exposure. The varicella vaccine prevents chickenpox and its complications, which can be more severe in adults. Vaccination in adults is particularly important for those in close contact with at-risk populations or those planning international travel. The HPV vaccine is crucial for preventing cancers associated with human papillomavirus infection, including cervical, anal, and oropharyngeal cancers. Originally targeted at adolescents, the HPV vaccine is increasingly recommended for adults, particularly young adults up to age 26, and in some guidelines up to age 45. The vaccine's role in preventing HPV-related diseases highlights its importance in adult immunization strategies. While MMR vaccines are often associated with childhood immunization, there is a growing recognition of their importance in adults, especially in response to measles outbreaks or in cases of international travel. Adults who have not been vaccinated or lack documented evidence of immunity may require MMR vaccination. This is particularly relevant for healthcare workers, college students, and individuals traveling to regions where these diseases are more prevalent. Pneumococcal vaccines are vital for preventing infections caused by Streptococcus pneumoniae, including pneumonia, meningitis, and bloodstream infections. The market includes vaccines such as PCV13 (pneumococcal conjugate vaccine) and PPSV23 (pneumococcal polysaccharide vaccine). These vaccines are especially recommended for older adults, individuals with chronic conditions, and those with weakened immune systems, due to their increased susceptibility to pneumococcal diseases. Influenza vaccines are recommended annually for all adults, particularly those at higher risk of complications. Hepatitis B vaccines are crucial for individuals at risk of liver infection due to factors like chronic illness or high-risk behaviors. Shingles vaccines are recommended for older adults to prevent herpes zoster, a painful condition caused by the reactivation of the varicella-zoster virus.


North America leads the adult vaccines market due to its advanced healthcare infrastructure, strong regulatory frameworks, and significant investment in vaccine research and development.

North America's dominance in the adult vaccines market can be attributed to a combination of factors that create a robust environment for vaccine development, distribution, and utilization. At the forefront is the region's highly advanced healthcare infrastructure, which supports comprehensive vaccination programs and efficient delivery systems. The United States and Canada boast state-of-the-art healthcare facilities, extensive networks of healthcare professionals, and well-established public health systems that are adept at implementing vaccination programs on a large scale. This infrastructure facilitates not only the development and production of vaccines but also their widespread distribution and administration, ensuring that vaccines reach diverse populations effectively. Additionally, North America benefits from strong regulatory frameworks that ensure the safety, efficacy, and quality of vaccines. In the United States, the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) play pivotal roles in regulating and recommending vaccines. The FDA's rigorous approval process, including pre-market evaluations and post-market surveillance, ensures that only safe and effective vaccines are available to the public. The CDC, through its Advisory Committee on Immunization Practices (ACIP), provides updated recommendations and guidelines that influence vaccination practices and policies. Similarly, Health Canada oversees vaccine approval and safety, maintaining high standards for vaccine quality and effectiveness. These regulatory bodies work to build public trust and ensure high vaccination rates, which are crucial for controlling disease outbreaks and preventing the spread of infections. Public health policies in North America also play a crucial role in leading the adult vaccines market. Governments in the region have prioritized vaccination as a key component of public health strategy, implementing policies that promote vaccine uptake and integrate vaccines into routine healthcare practices.

Considered in this report
• Historic year: 2018
• Base year: 2023
• Estimated year: 2024
• Forecast year: 2029

Aspects covered in this report
• Adult Vaccines Market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Types:
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease:
• Varicella
• Human Papilloma Virus
• Measles
• Mumps and Rubella
• Pneumococcal Disease
• Others

The approach of the report:
This report consists of a combined approach of primary and secondary research. Initially, secondary research was used to get an understanding of the market and list the companies that are present in it. The secondary research consists of third-party sources such as press releases, annual reports of companies, and government-generated reports and databases. After gathering the data from secondary sources, primary research was conducted by conducting telephone interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this; we have started making primary calls to consumers by equally segmenting them in regional aspects, tier aspects, age group, and gender. Once we have primary data with us, we can start verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations, and organizations related to the Adult Vaccines industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing and presentations, it will also increase competitive knowledge about the industry.